

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boan Biotech
博安生物

Shandong Boan Biotechnology Co., Ltd.

山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6955)

VOLUNTARY ANNOUNCEMENT TRANSFER OF SHARES BY CONTROLLING SHAREHOLDER

This announcement is published by Shandong Boan Biotechnology Co., Ltd. (the “**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company dated 11 January 2026 (the “**Announcement**”) in relation to, among other things, the transfer of H Shares in the capital of the Company (the “**Proposed Transfer**”) by the controlling shareholder of the Company, Luye Pharma Group Ltd. (“**Luye Pharma**”, together with its subsidiaries, the “**Luye Pharma Group**”). Unless the context otherwise requires, terms defined in the Announcement have the same meanings when used in this announcement.

The board of directors (the “**Board**”) of the Company has been informed by the Luye Pharma Group that it intends to arrange for a further on-market transfer by Shandong Luye Pharmaceutical Co., Ltd. (山东绿叶制药有限公司), a wholly-owned subsidiary of Luye Pharma, of 38,500,000 H Shares to the Issuer on 22 January 2026 as part of the Proposed Transfer in accordance with the terms of the subscription agreement related to the Exchangeable Preference Shares.

The Board does not expect such transfer to have any material adverse effect on the business operations of the Group.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua
*Chairlady, Chief Executive Officer and
Executive Director*

Yantai, the People's Republic of China, 21 January 2026

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua, Dr. Dou Changlin and Mr. Wang Shenghan; the non-executive directors of the Company are Mr. Liu Yuanchong, Ms. Li Li and Mr. Li Shixu; and the independent non-executive directors of the Company are Professor Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.